Diabetes News
2017-11-29
Benefits of Using a Dexcom G7 CGM During Pregnancy
Managing diabetes during pregnancy can be tough, but Dexcom Chief Operating Officer Jake Leach shares how a CGM can help.MORE
GoodRx Announces New Way for People to Access Lantus for $35
GoodRx partnered with Sanofi to offer $35 insulin coupons to all, regardless of their insurance status, for use at pharmacies nationwide. MORE
New Program Recognizes Leaders In Diabetes Care
Received stellar diabetes care? Encourage your providers to apply to be recognized as leaders in diabetes care.MORE
Vertex VX-880 Clinical Results Lead To Insulin-Independence
Here's what you need to know about Vertex's recent results from their stem-cell therapy for type 1 diabetes.MORE
Ketogenic Diet for Kids with Diabetes Carries Risk
The American Academy of Pediatrics warns against a ketogenic diet, a popular low-carbohydrate diet, for children with diabetes.MORE
Dexcom ONE Now Available in France
Dexcom ONE, a continuous glucose monitoring (CGM) system, is now available for people with diabetes in France.MORE
Beyond Type 2 Expands to Provide Resources to Canada
Canadians can now share their stories, get connected to the community and find critical resources on all things type 2 diabetes. MORE
New Pfizer Vaccine Available Fall 2023
The new COVID vaccine shot will soon be available for fall. This article will detail everything you need to know to protect yourself.MORE
How You Can Try a Dexcom CGM for Free
Learn why continuous glucose monitors (CGMs) are beneficial and how you can try the free 10-day Dexcom trial program.MORE
T1D Clinical Trial Search Engine Now Available In Spanish
Beyond Type 1 collaborates with Antidote Technologies and JDRF to launch the first-ever Spanish-language clinical trial search engine for type 1 diabetes.MORE
Project IMPACT: Bringing CGM Access to a Pharmacy Near You
Interview with Robert E. Nichols, PharmD, BCPS, Clinical Pharmacist, who is participating in the pilot program for better CGM access. MORE
Beyond Type Run Marathon Team Reaches New Milestones in 2023
Beyond Type Run, the stereotype-smashing team of runners proves anybody living with diabetes can go the distance despite their diagnosis.MORE
Moms’ Night Out Aims to Support Caregivers of Type 1 Diabetes
“Moms’ Night Out” expands after exciting launch. Attend an upcoming event for mothers of children with diabetes in these three cities!MORE
JDRF’s Children’s Congress: Finding A Cure For Type 1 Diabetes
Learn more about JDRF, its mission behind the biannual Children’s Congress and the impact of this year's event.MORE
Tandem’s Mobi Approved by the FDA
Tandem’s newest insulin pump, Mobi, was approved by the FDA for people with diabetes age six and up. Here's what you need to know!MORE
A Year in Review: Advancements in Diabetes Tech + Research
This session reviewed the advances and discoveries in research and technology for people living with diabetes over the past year.MORE
Senseonics + UnitedHealthcare Expanding CGM Access
Senseonics announced that UnitedHealthCare will now cover their Eversense E3 implantable CGM, starting July 1, 2023.MORE
Medtronic’s MiniMed 780G Receives FDA Approval
The FDA has approved Medtronic’s MiniMed 780G, the newest automated insulin dosing (AID) system on the market. MORE
Eli Lilly’s Baqsimi Acquired by Amphastar: What This Means for People With Diabetes
Eli Lilly’s nasal glucagon, Baqsimi, has been acquired by Amphastar. Here’s what you should know about the change and its significance.MORE
Mark Cuban’s Cost Plus Drugs Makes Diabetes Products More Affordable
Mark Cuban's Cost Plus Drugs Company just announced that they offer Janssen's Invokana, Invokamet and Invokamet XR for type 2 diabetes.MORE
Why Diabetes Should be Screened by Age Instead of Weight
Many cases of diabetes may be missed by screening only by weight instead of age, especially for some racial and ethnic groups.MORE
California Partners with Civica Rx to Make More Affordable Insulin
California has signed a contract with Civica Rx to make more affordable insulin for Americans with diabetes. Here’s what you should know about their partnership, CalRx.MORE
Sanofi to Slash Price of Lantus by 78%, Cap Out-of-Pocket Costs to $35
Sanofi has capped monthly out-of-pocket costs for Lantus to $35 for all with commercial insurance and will cut the price of Lantus by 78%, effective January 1, 2024. MORE
Novo Nordisk to Slash Insulin Prices by over 65%
Novo Nordisk announced that starting January 1st, 2024 they will be lowering the list price of several of their insulins by 65-70%.MORE
Freestyle Libre 2 and 3 Receive FDA Clearance for Integration with Automated Insulin Delivery Systems
Abbott, makers of the Freestyle Libre 2 and 3, modified their sensors to enable integration with automated insulin delivery systems. Here’s what you should know!MORE
$25 List Price + $35 Copay Caps: Lilly’s New Insulin Cost Reductions
On March 1, 2023, insulin manufacturer Lilly announced expanded insulin cost-saving measures for people with and without health insurance coverage.MORE
FDA Approves Teplizumab to Delay Onset of Type 1 Diabetes
Teplizumab binds to certain immune system cells and delays the progression of T1D.MORE
This New App is Designed to Make Tracking Your Insulin Easier
If you use Lilly brand insulin, this new connected platform is designed to make tracking your diabetes data a lot easier. MORE
Say Hello to BeyondType2.org in French, German and Italian!
BeyondType2.org now offers critical resources in five languages for people living with and impacted by type 2 diabetes.MORE
The Future of Insulin — Will It Be Affordable for the People Who Need It?
Research is showing promising advancements with new weekly oral and injectable insulins—but will they actually be affordable?MOREDiabetes + Dementia: Using Nasal Insulin to Improve Brain Function
With rising rates of obesity in both type 1 and type 2 diabetes, understanding the impact on long-term brain health and function is critical.MORE
Women + Exercise: It’s Complicated
Women living with type 1 diabetes are told exercise will help better manage their diabetes. That’s easier said than done. MORE
Reaching Everyone — Health Disparities in Physical Activity
People living with diabetes are told to just exercise more to better manage their diabetes. Here is why its not that simple. MOREAnother Reminder that Racial/Ethnic Inequality Exists in Diabetes Care
Despite the variety of diabetes medications and technology, race and ethnicity still weigh heavily on a person’s access to these life-saving tools.MORE
Race, Racism, and Diabetes Research
Diabetes care and research is still drastically impacted by racist practices. It’s time to call the racism out. MOREMounjaro: Its Powerful Potential to Treat Type 2 Diabetes & Obesity
Experts discuss the impressive impact and future potential of using Mounjaro (tirzepatide) to treat obesity and type 2 diabetes.MOREResearch: Practical Use of Closed-Loop Insulin Pumps
Closed-loop insulin pump technology is a game-changer for those taking insulin. Here are essential tips to using them in day-to-day life.MOREAccess to Insulin: In the United States
Despite the growing variety of insulin and technology, access to this life-saving drug continues to be a dire problem in the United States.MOREAccess to Insulin: In Low-Income Countries
In many countries, a person with diabetes may walk for four days to get a vial of short-acting insulin and seven to 10 days for long-acting.MORE
Promising New Drug Leads to 22.5% Weight Loss in Adults Living with Obesity
The latest study on a new drug is making headlines for its impressive ability to help patients lose weight.MORE
Stem Cell Therapy for Type 1 Diabetes: Patient Achieved Insulin Independence on Day 270
A patient in the Vertex Pharmaceutical’s clinical trial using stem-cell therapy to treat type 1 diabetes has achieved insulin independence on Day 270 of the trial. MORE
Coverage of Dexcom G6 CGM Now Improved with TRICARE
TRICARE healthcare members can now receive the Dexcom G6 continuous glucose monitor (CGM) under pharmacy benefits.MORE
The Affordable Insulin Now Act: A Step Toward Federal Legislation
The Affordable Insulin Now Act, if passed in its current form, could help bring down the cost of insulin for millions of insured people with diabetes.MORE
FreeStyle Libre 2 Now More Easily Accessible for Military Members Through TRICARE
Military members with TRICARE now have easier access to Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM).MORE
COVID-19 Pushes FDA Approval of Breakthrough Device Designation for Dexcom CGM in Hospital Settings
The FDA has granted Breakthrough Device Designation for Dexcom CGM in hospital settings after the pandemic highlighted essential care needs for patients with diabetes.MORE
Eversense E3 Continuous Glucose Monitor Gains FDA Approval, Offers Extended Wear-Time
The Eversense E3 continuous glucose monitor (CGM) is an exciting advancement for the diabetes community, with improved wear-time and accuracy.MORE
Omnipod 5 Receives FDA Approval
Omnipod 5, a closed-loop tubeless insulin pump with smartphone control that integrates with the Dexcom G6 continuous glucose monitor, has now received FDA approval.MORE
Inside the Drug Pricing Investigation from the House Oversight and Reform Committee
The results of the most recent report from the committee make things clear for the United States — the need for access to affordable healthcare is direr than ever.MORE
The Potential Impact of Build Back Better on American Healthcare
Dive into the basics of Build Back Better, why people with diabetes should follow the bill as it progresses, and the impact it could have on your health.MORE
Mark Cuban’s New Online Pharmacy Provides Affordable Access to Some Common Prescription Drugs
Mark Cuban's latest investment in the pharmaceutical industry offers common generic prescription medications (not including insulin) at a fraction of the cost.MORE
A Win for T1D in California: Senate Bill 97 Signed Into Law
The bill requires type 1 diabetes informational materials to be developed for the parents and guardians of pupils in California schools.MORE
Beyond Type 1 Launches Web Platform in Arabic
Diabetes information, stories, and news are now available in Arabic at ar.beyondtype1.org.MORE
COVID-19 Vaccines For Kids Ages 5 to 11 With Diabetes: What to Know
COVID-19 vaccines are now available for kids age 5+! Learn about safety and managing side effects for kids with type 1 diabetes.MORE
Stem-Cell Therapy for Type 1 Diabetes Reduced Patient’s Insulin Needs by 91%
The early results of a clinical trial using stem-cell therapy to treat type 1 diabetes reduced the patient’s insulin needs by 91%.MORE
Lilly Announces Lower List price for Insulin Lispro
The company will lower the list price of the generic version of Humalog in the U.S. by an additional 40 percent starting January 1, 2022.MORE
Lilly Issues Voluntary Nationwide Recall of One Lot of Glucagon Emergency Kit
Lilly announced the voluntary recall of lot D239382D, Expiration April 2022 of Glucagon Emergency Kits.MORE
The Latinx Diabetes Initiative Provides Culturally Tailored Care To Latinx Patients With Diabetes
Andreina Millan Ferro is centering culturally sensitive diabetes care for Latinx patients with diabetes at the Latinx Diabetes Initiative.MORE
Yarishdy Mora Is Empowering Youth Through Diabetes Education In Mexico
Yarishdy Mora is the director of the Youth Health Program for Project HOPE in Mexico. She creates platforms that help youth learn about diabetes. MORE
Overweight Adults to Now Be Screened for Type 2 Diabetes At 35
The U.S. Preventive Services Task Force now recommends overweight and obese adults to get screened for Type 2 diabetes at the age of 35.MORE
Pandemic Homelessness Disproportionately Impacts People With Diabetes
An American Diabetes Association report found that pandemic homelessness hit people with diabetes 48 times harder.MORE
Abbott’s FreeStyle Libre 2 App Receives FDA Clearance
On August 2, 2021, the FDA approved the FreeStyle Libre 2 app for adults and children with diabetes, allowing user to access glucose readings directly from their iPhone.MORE
FDA Approves Senza®, Nevro’s High Frequency Spinal Cord Stimulation Therapy For PDN
The Senza System has been approved by the FDA for the treatment of chronic pain associated with painful diabetic neuropathy.MORE
Semglee Receives FDA Approval as First Interchangeable Biosimilar Insulin
Semglee becomes the first interchangeable biosimilar insulin product for the treatment of type 1 and type 2 diabetes.MORE
Providing Culturally Sensitive LGBTQ+ Diabetes Health Care
Culturally sensitive LGBTQ+ diabetes health care can decrease stigma and advance diabetes care access for the LGBTQ community. MORE
High Risk Pregnancy – Mitigating Risks for Type 1 Diabetes + Black Maternal Health Outcomes
Ariel Lawrence, a diabetes advocate and Black mother with type 1 diabetes, shares how she navigated her pregnancy. MORE
Addressing Disparities in Pediatric Diabetes Treatment In Philadelphia
Terri Lipman shares how incorporating community health workers can tackle disparities in pediatric diabetes treatment. MORE
FDA Issues CRL for Teplizumab, Investigational Candidate to Delay the Onset of T1D
The FDA issues a complete response letter to Provention Bio as part of an update for Teplizumab to delay the onset of type 1 diabetes.MORE
Combating Diabetes Disparities Among The Hispanic Population
At ADA 2021, David Marrero discusses how culturally tailored care can combat diabetes disparities among the Hispanic population.MORE
Walmart Launches Lower-Cost Analog Insulin: ReliOn NovoLog
ReliOn NovoLog will be available at Walmart and Sam's Club pharmacies for $72.88 per vial and $85.88 per box of five FlexPens.MORE
Preliminary Findings On Depression Among African American and Latino Parents of Children With T1D
Samantha Carreon shares preliminary data on the TEAM study which found higher rates of depression among African American and Latino parents.MORE
Making Broadway More Accessible With JP Qualters
JP Qualters shares his experience on Broadway as a person living with type 1 diabetes and his aspirations for the theater industry.MORE
Zegalogue® Is Now Commercially Available In The United States
Zegalogue®, also known as dasiglucagon, is now commercially available in the U.S. for the treatment of severe hypoglycemia.MORE
Medicare Loosens Restrictions on Continuous Glucose Monitor Coverage
Medicare revised its local coverage determination policy to remove requirements for continuous glucose monitor coverage.MORE
Supreme Court Votes To Keep The ACA Intact
The Affordable Care Act (ACA) provides health care to millions of Americans. The Supreme Court voted 7-2 to keep the ACA intact.MORE
COVID-19 Vaccines And Diabetes: Vaccine Access Issues For People Of Color
Communities of color with diabetes face a myriad of barriers when it comes to vaccine access. Experts share how the U.S. can achieve vaccine equity.MORE
Michelle L. Litchman Focuses On Diabetes Program Accessibility For People Who Are Deaf
Michelle L. Litchman was named a Betty Irene Moore Nurse Fellow. She will focus on diabetes program accessibility for people who are deaf.MORE
Test Strip Subscription Guide
We compiled a rundown of popular companies that offer test strip subscription services and researched each of them to give you some important info.MORE
Omnipod 5 Pivotal Trial Data Published
Data from the pivotal trial shows that the Omnipod 5 improves time-in-range, and reduces HbA1c and mean glucose levels. MORE
Breaking News From ATTD 2021
This year, ATTD 2021 will be held virtually where developers and clinicians will present their new diabetes technology and research.MORE
Survey Finds the Pandemic Increased Mental Health Concerns Among People With Diabetes
Cecelia Health conducted a survey that revealed increased mental health concerns among people with diabetes during the COVID-19 pandemic. MORE
FDA Advisory Committee Votes 10-7 To Recommend Approval of Teplizumab For Delay Of Type 1 Diabetes
Teplizumab is an investigational candidate proven to delay the onset of type 1 diabetes. The FDA advisory committee reviews its efficacy.MORE
Combating Bullying: How One Person With Diabetes Fought To Test Her Blood Sugar In The Workplace
Sheri Byrne shares her experience on how she fought workplace bullying due to diabetes and advocated for herself.MORE
Bigfoot Unity™ Diabetes Management System Receives The Green Light From The FDA
Bigfoot Unity™, a one-of-a-kind diabetes management system with smart pen caps received FDA approval on May 10, 2021 and will reach select diabetes clinics this spring. MORE
Asian Isn’t A Monolith: Why More Specific Data Matters in Diabetes Research
Data on how diabetes impacts specific ethnic groups could help us better support people within Asian American Pacific Islander communities.MORE
Type 1 Diabetes + Ramadan: Here’s How a Few People Are Observing
People with diabetes face their own set of challenges when observing Ramadan. Two people with diabetes share their experiences. MORE
The PROTECT Study
The PROTECT Study aims to understand how the investigational medicine, teplizumab, works in children and young adults who have recently been diagnosed with T1D, as well as assessing if there are any s...MORE
Chris Hahm’s Uphill Battle: The Severe Underfunding of AAPI Diabetes Research
H. Chris Hahm shares her challenges of conducting diabetes research focused on the AAPI community, research that is severely underfunded.MORE
CDC and FDA Call for Pause on Johnson & Johnson Vaccine
After six cases of rare blood clots, the CDC and FDA has advised healthcare professionals to pause on distributing the Johnson and Johnson vaccine.MORE
FDA Approves New Glucagon Option from Zealand Pharma
Available in June 2021, the FDA approved Zealand Pharma’s Zeagalogue, a new form of glucagon for people with insulin-dependent diabetes.MORE
Two Pillars in the Diabetes Community Unite to Serve Millions Living with Diabetes
The partnership will feature combined resources, strategies, and tactics to better serve people living with type 1 diabetes, type 2 diabetes, and prediabetes.MORE
JDRF Announces New Center of Excellence to Advance T1D Research
On February 23, 2021, JDRF announced the launch of the JDRF Center of Excellence in collaboration with the Harvard Stem Cell Institute in New England.MORE
Get the Facts on Insulin Pricing + The Presidential Transition
A flurry of misinformation is stoking fears that the Biden Admin paused or reversed a previous Trump Admin policy that lowered the price of insulin. MORE
New Year, New Administration: What’s Coming For US Healthcare Policy
With a new governmental administration, it is likely we will see notable and impactful movement in healthcare policy. What can we expect? MORE
Congress Renews Funding for Special Diabetes Program
On Dec 22, 2020, Congress renewed the Special Diabetes Program, providing $150 million annually in type 1 diabetes research funding until 2023MORE
JDRF Launches Program to Advance Universal Screening for Type 1 Diabetes
T1Detect is a new screening initiative designed to make early detection of type 1 diabetes easier and more accessible to a broad population. MORE
Diabetes + COVID Vaccines: What You Need to Know
If you have diabetes, here’s everything you need to know about the COVID-19 vaccines.MORE
Amazon Launches Online Pharmacy
Amazon Pharmacy, launched on November 17, delivers medications and prescription refills - such as insulin - with Prime membership 2-day shipping.MORE
Fourth Major Insulin Manufacturer Enters US Market with Semglee Launch
Semglee (insulin glargine), from Mylan and Biocon, is now available by prescription in the United States in vial and pre-filled pen presentations.MORE
With SAG-AFTRA Healthcare Changes, Can T1Ds Stay in the Arts?
With recently announced SAG-AFTRA healthcare changes, do the majority of people with T1D realistically have the option to choose a profession in the arts? MORE
JDRF Announces Updated Strategy, Renewed Focus in Light of COVID-19
Amidst COVID-19, JDRF prioritizing work in their portfolio that they see as having the highest likelihood for cures and life changing advances for diabetes.MORE
